Hashemi MO, Akbari ME. Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study. Sci Rep. 2023 Oct 4;13(1):16719. doi: 10.1038/s41598-023-43186-8. PMID: 37794050; PMCID...
1.Abbasvandi F, Bayat M, Akbari A, Shojaeian F, Zandi A, Rahmani J, Hashemi MO, Akbari ME. Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study. Sci Rep. 2023 Oct 4;13(1):16719. doi: 10.1038/s41598-023-43186-8. PMID: 37794050; ...
[15] Krop I E, Kim S B, Martin A G, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival r...
[3]de Nonneville A, Houvenaeghel G, Cohen M, Sabiani L, Bannier M, Viret F, Goncalves A, Bertucci F. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer. 2022;176:181–188. [4]De...
[3]de Nonneville A, Houvenaeghel G, Cohen M, Sabiani L, Bannier M, Viret F, Goncalves A, Bertucci F. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer. 2022;176:181–188. ...
Neoadjuvant chemotherapy can improve the overall survival rate of patients with inflammatory breast cancer, and surgery and radiotherapy can reduce the risk of local recurrence.4 At present, inflammatory breast cancer still has a very poor prognosis, and new modes of control must be explored to ...
In univariate log-rank testing, HER2-positive patients were significantly more likely to relapse on tamoxifen, giving 5-year breast cancer-specific survival rates of 68% compared with 96% for the HER2-negative group (P<0.001, Figure 1). This significance was retained in Cox regression analysis ...
Patients diagnosed with HER2-negative/low breast cancer, treated at the UMAE Oncology Hospital of the CMN Siglo XXI, from January 2018 to December 2022, were included. OS and disease-free survival (DFS) were calculated using Kaplan-Meier curves, and the impact of HER2-low expression on OS ...
survival rate from 77% to 88.3% (HR, 0.50;P < 0.001) when compared to trastuzumab for the treatment of patients with residual invasive HER2+breast cancer after neoadjuvant therapy. T-DM1 was administered for a total of fourteen 3-week cycles after breast cancer surgical treatment40. T-...
Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy There is evidence that increased absolute levels of the HER2 receptor in breast cancer positively correlates with a clinical benefit from anti-HER2...